Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021

SELL
$4.59 - $9.04 $58,756 - $115,721
-12,801 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$1.51 - $6.3 $19,329 - $80,646
12,801 New
12,801 $63,000

Others Institutions Holding ONCT

About Oncternal Therapeutics, Inc.


  • Ticker ONCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,517,200
  • Market Cap $41.6M
  • Description
  • Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...
More about ONCT
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.